Shukra Pharmaceuticals reports Q2 and half-year financials

Shukra Pharmaceuticals Ltd. has publicly released its standalone unaudited financial results for the second quarter and half-year period concluding on September 30, 2025. These results were published in the Business Standard (English) and Jai Hind (Gujarati) newspapers, in compliance with Regulation 47 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015.

The announcement was made by Bhoomiben Patel, director, and submitted to the Corporate Relationship Department of BSE Limited on November 14, 2025. The company's scrip code is 524632.

Further details regarding the specific financial figures for the second quarter and half-year, such as revenue, profit, or loss, are not provided in this specific document. The release confirms the act of publication and adherence to regulatory standards.